99 Grants (Page 1 of 4)
2021
CB2 Cannabinoid Mechanisms for Suppressing Opioid Tolerance and Dependence
Hohmann, Andrea G and MACKIE, KENNETH P
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5R01DA047858-03), $517,184USD, 2019-04-15 -- 2024-02-29
 
INTEGRATIVE PREDOCTORAL TRAINING IN DRUG ABUSE RESEARCH AT INDIANA UNIVERSITY
Hohmann, Andrea G and MACKIE, KENNETH P
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5T32DA024628-12), $214,088USD, 2008-07-01 -- 2025-06-30
 
Modulation of pain mechanisms by cannabis-derived phytochemicals.
MACKIE, KENNETH P and PENNER, REINHOLD
National Institutes of Health (NIH), National Center for Complementary and Alternative Medicine (NCCAM) (ID: 1R01AT011162-01A1), $663,415USD, 2020-12-01 -- 2025-11-30
 
Perinatal cannabinoids delay KCC2 expression and lead to neurodevelopmental abnormalities
MACKIE, KENNETH P and MANZONI, OLIVIER J
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5R01DA046196-04), $309,837USD, 2018-08-01 -- 2023-06-30
 
Sex-specific critical periods determine the effects of cannabinoids on the mesocorticolimbic system
MACKIE, KENNETH P and MANZONI, OLIVIER J
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5R01DA043982-05), $310,657USD, 2017-08-01 -- 2022-05-31
2020
CB2 Cannabinoid Mechanisms for Suppressing Opioid Tolerance and Dependence
Hohmann, Andrea G and MACKIE, KENNETH P
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5R01DA047858-02), $517,184USD, 2019-04-15 -- 2024-02-29
 
INTEGRATIVE PREDOCTORAL TRAINING IN DRUG ABUSE RESEARCH AT INDIANA UNIVERSITY
Hohmann, Andrea G and MACKIE, KENNETH P
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 2T32DA024628-11), $211,858USD, 2008-07-01 -- 2025-06-30
 
Perinatal cannabinoids delay KCC2 expression and lead to neurodevelopmental abnormalities
MACKIE, KENNETH P and MANZONI, OLIVIER J
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5R01DA046196-03), $309,754USD, 2018-08-01 -- 2023-06-30
 
Role of CB2 in Analgesic Mechanisms
Hohmann, Andrea G and MACKIE, KENNETH P
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5R01DA041229-05), $351,000USD, 2016-04-15 -- 2021-01-31
 
Sex-specific critical periods determine the effects of cannabinoids on the mesocorticolimbic system
MACKIE, KENNETH P and MANZONI, OLIVIER J
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5R01DA043982-04), $309,985USD, 2017-08-01 -- 2022-05-31
2019
Cannabinoids play a central role in cerebellar development
Kalinovsky, Anna and MACKIE, KENNETH P
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5R21DA044000-02), $196,875USD, 04/01/2018 -- 03/31/2020
 
CB2 Cannabinoid Mechanisms for Suppressing Opioid Tolerance and Dependence
Hohmann, Andrea G and MACKIE, KENNETH P
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 1R01DA047858-01), $517,184USD, 04/15/2019 -- 02/29/2024
 
Perinatal cannabinoids delay KCC2 expression and lead to neurodevelopmental abnormalities
MACKIE, KENNETH P and MANZONI, OLIVIER J
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5R01DA046196-02), $310,099USD, 08/01/2018 -- 06/30/2023
 
Role of CB2 in Analgesic Mechanisms
Hohmann, Andrea G and MACKIE, KENNETH P
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5R01DA041229-04), $351,000USD, 04/15/2016 -- 01/31/2021
 
Sex-specific critical periods determine the effects of cannabinoids on the mesocorticolimbic system
MACKIE, KENNETH P and MANZONI, OLIVIER J
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5R01DA043982-03), $297,979USD, 08/01/2017 -- 05/31/2022
2018
Cannabinoids play a central role in cerebellar development
Kalinovsky, Anna and MACKIE, KENNETH P
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 1R21DA044000-01A1), $236,250USD, 04/01/2018 -- 03/31/2020
 
Does GPR119 mediate the beneficial metabolic effects of THC?
MACKIE, KENNETH P
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5R21DA044004-02), $177,187USD, 04/01/2017 -- 03/31/2019
 
Exploiting CB2 Functional Selectivity for Therapeutic Benefit
MACKIE, KENNETH P
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5P01DA009158-19-5294), $234,500USD, 2018
 
Perinatal cannabinoids delay KCC2 expression and lead to neurodevelopmental abnormalities
MACKIE, KENNETH P and MANZONI, OLIVIER J
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 1R01DA046196-01), $323,667USD, 08/01/2018 -- 06/30/2023
 
Role of CB2 in Analgesic Mechanisms
Hohmann, Andrea G and MACKIE, KENNETH P
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5R01DA041229-03), $315,900USD, 04/15/2016 -- 01/31/2021
 
Sex-specific critical periods determine the effects of cannabinoids on the mesocorticolimbic system
MACKIE, KENNETH P and MANZONI, OLIVIER J
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5R01DA043982-02), $298,313USD, 08/01/2017 -- 05/31/2022
2017
Cannabinoid Modulation of Cell Function
MACKIE, KENNETH P
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5K05DA021696-10), $139,326USD, 10/18/2005 -- 03/31/2018
 
Does GPR119 mediate the beneficial metabolic effects of THC?
MACKIE, KENNETH P
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 1R21DA044004-01), $196,406USD, 04/01/2017 -- 03/31/2019
 
Exploiting CB2 Functional Selectivity for Therapeutic Benefit
MACKIE, KENNETH P
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5P01DA009158-18-5294), $234,500USD, 2017
 
Role of CB2 in Analgesic Mechanisms
Hohmann, Andrea G and MACKIE, KENNETH P
National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) (ID: 5R01DA041229-02), $315,900USD, 04/15/2016 -- 01/31/2021